Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Galapagos Discovers Novel Candidate Drug to Treat Breast Cancer

Published: Monday, April 22, 2013
Last Updated: Monday, April 22, 2013
Bookmark and Share
GLPG1790 has high efficacy against triple-negative breast cancer.

Galapagos NV has announced that it has developed GLPG1790, a novel candidate drug to treat breast cancer.

GLPG1790 has shown high activity against breast tumors that are triple-negative, for which the absence of estrogen (ER), progesterone (PR) or HER2 receptors affects the prognosis for recovery, and no targeted therapeutic options are currently available.

Breast cancer is a disease in which tumor cells form in the breast tissue; it is one of the most common types of cancer in women. There are many different types of breast cancer, and as a result, there are many options for treatment.

Targeted drug treatments such as Herceptin® and Avastin® attack specific types of breast cancer cells.

Decisions about the best possible treatment with targeted drugs are based on tests for the presence of ER, PR and HER2. Triple-negative breast cancer (tumor cells that have no ER, PR and HER2) accounts for one-fifth of breast cancers, and it usually affects young women. There are no targeted drugs available for patients with triple-negative breast cancer.

Candidate drug GLPG1790 is a selective and potent inhibitor of a novel breast cancer target; the candidate drug has proven to be highly active against triple-negative breast cancer in a mouse xenograft model where it completely blocks tumor growth.

GLPG1790 has good drug-like properties, and safety/tolerability studies with the candidate drug look favorable.

Galapagos will initiate preclinical studies with GLPG1790, and expects to initiate the first clinical trials in humans within one year. This novel program is fully proprietary to Galapagos.

"GLPG1790 is the result of a multi-year research program on a novel mechanism of action discovered with our target discovery platform," says Dr Piet Wigerinck, Galapagos CSO.

Dr Wigerinck continued, "We are pleased to have developed a targeted approach towards triple-negative breast cancer. Targeted approaches in oncology typically show good efficacy and less toxicity than chemotherapy."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Galapagos Starts Phase 1 Study
Company has announced the start of a Phase 1 study with potentiator GLPG2451 for cystic fibrosis (CF).
Tuesday, May 10, 2016
Galapagos, Abbvie Expand Cystic Fibrosis Collaboration
Company has announced that it has expand cystic fibrosis collaboration with Abbvie to reflect the successful expansion of their CF portfolio.
Friday, April 29, 2016
Galapagos Reports Additional Data with Filgotinib
Company has reported 20-week results from its FITZROY study with the investigational, selective JAK1 inhibitor filgotinib in Crohn’s disease.
Saturday, April 23, 2016
Galapagos and MorphoSys initiate Phase 1 study
Company has initiated phase 1 study with MorphoSys AG in joint antibody program MOR106.
Friday, April 08, 2016
Galapagos Initiates a Phase 2a Study with GLPG1690
Company has announced that it has initiated a phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients.
Thursday, April 07, 2016
Galapagos Starts Saphira Phase 2 Study With Glpg1837 In Cystic Fibrosis Patients
Company has announced its Phase 2 exploratory program of GLPG1837 in patients with cystic fibrosis.
Wednesday, February 17, 2016
Galapagos and Gilead Complete Closing of their Global Collaboration for Filgotinib
Triggers an upfront license fee payment of $300 million and equity investment of $425 million.
Thursday, January 21, 2016
Galapagos Advances CF Clinical Development
Initiation of Phase 1 study with corrector GLPG2222, earning Galapagos a $10 million milestone payment from AbbVie.
Wednesday, January 20, 2016
Galapagos Advances Triple Combination Therapy in Cystic Fibrosis
GLPG2665 enters pre-clinical development and completes the first Galapagos-AbbVie triple combination therapy.
Wednesday, October 21, 2015
Positive Safety and Tolerability for Novel Potentiator GLPG1837
Company presents topline Phase 1 results at the North American Cystic Fibrosis Conference in Phoenix.
Saturday, October 10, 2015
Galapagos Presents Promising Pre-clinical and Phase 1 Results
Company presents results for autotaxin inhibitor GLPG1690 at ERS Annual Meeting.
Saturday, September 26, 2015
Galapagos to Advance Filgotinib to Phase 3 in Rheumatoid Arthritis
Phase 3 start in RA expected in early 2016.
Saturday, September 26, 2015
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Tuesday, August 25, 2015
Patient Recruitment Completed in FITZROY Phase 2 Crohn's Disease Study
First selective JAK1 inhibitor in Phase 2 in Crohn's disease.
Friday, August 07, 2015
Galapagos Completes Recruitment for ORIGIN Phase 2 Trial
Recruitment for the Phase 2 Proof-of-Concept study with GPR84 inhibitor GLPG1205 in ulcerative colitis patients.
Saturday, June 20, 2015
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
New NIH-EPA Research Centers to Study Environmental Health Disparities
Scientists will partner with community organizations to study these concerns and develop culturally appropriate ways to reduce exposure to harmful environmental conditions.
Structure of Essential Digestive Enzyme Uncovered
Using a powerful combination of techniques from biophysics to mathematics, researchers have revealed new insights into the mechanism of a liver enzyme that is critical for human health.
Air Pollution Linked to Heart Disease
10-year project revealed air pollutants accelerate plaque build-up in arteries to the heart.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Following Tricky Triclosan
Antibacterial product flows through streams, crops.
Vitamin A May Help Improve Pancreatic Cancer Chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL).
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!